International Cancer Conference Journal

, Volume 6, Issue 2, pp 65–69 | Cite as

Concurrent high-grade serous carcinoma and borderline tumor demonstrating different chemo-sensitivity

  • Momoko Inoue
  • Masataka Takenaka
  • Masaharu Fukunaga
  • Seiji Isonishi
Case report


Ovarian high-grade serous adenocarcinoma responds well to regular platinum/taxane chemotherapy, while borderline tumor survives and demonstrates persistent disease. A 69-year-old Japanese woman was suspected for having advanced ovarian carcinoma. MRI showed cystic tumor containing solid component of the right adnexal region with massive ascites and peritoneal dissemination. Serum CA125 was elevated to 203 µ/ml; however, no remote metastases were detected. Laparotomy revealed that peritoneal carcinomatosis spreads out to omentum and subphrenic area. Omentum was partially removed with big tumor nodules that histologically demonstrated the high-grade serous adenocarcinoma with positive ascites cytology. After 6 cycles of postoperative chemotherapy with docetaxel and carboplatin, she received second surgery where the known residual bilateral adnexa and all of the persistent tumors were perfectly resected. Pathological examination of the tumor revealed serous borderline tumor with microinvasion and no evidence of residual high-grade serous carcinoma with negative ascites cytology. This is the extremely rare case of concurrent high-grade serous carcinoma and borderline tumor demonstrating differential chemo-sensitivity.


High-grade serous carcinoma Serous borderline tumor Chemo-sensitivity 



Authors would like to thank English Lectures Paul Raine, Jikei University School of Medicine for their comments in English.

Compliance with ethical standards

Conflict of interest

The authors report no conflicts of interest.

Informed consent

This patient has already died of disease more than a year ago. At this moment, we could not keep track of the patient’s guardian or next of kin and the written consent could not be available. In the report described here, all personal details of the patient were removed from the case report to ensure that the patient cannot be identified.


  1. 1.
    Gilks CB (2004) Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data. Int J Gynecol Pathol 23:200–205.Google Scholar
  2. 2.
    Ho C-L, Kurman RJ, Dehari R et al (2004) Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res 64:6915–6918CrossRefPubMedGoogle Scholar
  3. 3.
    Russell HE, McCluggage WG (2004) A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes. J Pathol 203:617–619Google Scholar
  4. 4.
    Shih IeM, Kurman RJ (2004) Ovarian tumorigenesis. A proposed model based on morphological and molecular genetic analysis. Am J Pathol 164:1511–1518Google Scholar
  5. 5.
    Singer G, Shih IM, Truskinovsky A et al (2003) Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma. Int J Gynecol Pathol 22:37–41CrossRefPubMedGoogle Scholar
  6. 6.
    Dehari R, Kurman RJ, Logani S et al (2007) The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumours and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis. Am J Surg Pathol 31:1007–1012CrossRefPubMedGoogle Scholar
  7. 7.
    Parker RL, Clement PB, Chercover DJ, Sornarajah T, Gilks CB et al (2004) Early recurrence of ovarian serous borderline tumour as high-grade carcinoma: report of two cases. Int J Gynecol Pathol 23:265–272CrossRefPubMedGoogle Scholar
  8. 8.
    Quddus MR, Rashid LB, Hansen K et al (2009) High-grade serous carcinoma arising in a low-grade serous carcinoma and micropapillary serous borderline tumour of the ovary in a 23 year-old woman. Histopathology 54:771–7733CrossRefPubMedGoogle Scholar
  9. 9.
    Schlumbrecht MP, Sun CC, Wong KN et al (2011) Clinicodemographic factors influencing outcomes in patients with low-grade serous ovarian carcinoma. Cancer 117(16):3741–3749CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Clinton B, Glenn McCluggage W (2012) Low grade ovarian serous neoplasms (low-grade serous carcinoma and serous borderline tumor) associated with high-grade serous carcinoma or undifferentiated carcinoma: report of a series of cases of an unusual phenomenon. Am J Surg Pathol 36:368–375CrossRefPubMedGoogle Scholar
  11. 11.
    Prat J, de Nictolis M (2002) Serous borderline tumors of tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion. Am J Surg Path 26:1111–1128CrossRefPubMedGoogle Scholar

Copyright information

© The Japan Society of Clinical Oncology 2017

Authors and Affiliations

  • Momoko Inoue
    • 1
  • Masataka Takenaka
    • 1
  • Masaharu Fukunaga
    • 2
  • Seiji Isonishi
    • 1
  1. 1.Department of Obstetrics and GynecologyJikei Daisan HospitalTokyoJapan
  2. 2.Department of PathologyJikei Daisan HospitalTokyoJapan

Personalised recommendations